Skip to main content
Premium Trial:

Request an Annual Quote

Cogenics Partners with SinoGenoMax in China

NEW YORK (GenomeWeb News) — Beijing-based genomics research services company SinoGenoMax will offer Cogenics’ genotyping services in China, Cogenics' parent company, Clinical Data, said today.

"Our partnership with SinoGenoMax provides us with an established presence in China and an experienced international service partner who operates with similar platforms and high quality standards," Cogenics Global Manager Michael Lutz said in a statement. "The extensive pharmaceutical and biotechnology infrastructure and large number of clinical trials conducted in China make this an increasingly important market for clinical genotyping services."

SinoGenoMax CEO Danny Ching said the partnership also "represents a significant opportunity for SinoGenoMax to widen its international spectrum."

Cogenics has facilities in North Carolina, Texas, the United Kingdom, France, and Germany.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.